期刊文献+

不同表位60000SSA抗原免疫小鼠的反应 被引量:1

Reactions after mice immunized with multiple antigenic peptides of 60 000 SSA antigen
原文传递
导出
摘要 目的了解不同表位60000SSA抗原免疫小鼠后的反应,能否产生相应的抗体及不同的组织损伤。方法用60000SSA的多倍体寡肽抗原(MAPs)免疫小鼠,利用酶联免疫吸附法(ELISA)检测其是否产生了相应的自身抗体。并取其心肝肾等组织器官行病理学及免疫组织化学检查。结果各组小鼠均产生了抗多个表位的抗体.尤其是482~495组小鼠除产生抗482~495MAP抗体外,还对198-210组、212~219组、449~460组MAPs发生了免疫反应。但其余各组小鼠产生的抗体似无明显规律性。佐剂组小鼠及正常小鼠心、肝、肾脏免疫组织化学均呈阴性:482--495组、166~180组、401~411组小鼠心脏免疫组织化学均呈阴性,肝脏免疫组织化学80%呈阳性,部分小鼠肾脏免疫组织化学呈可疑阳性;各组小鼠心、肝、肾脏切片HE染色均未见明显形态学异常,与正常鼠无明显差异。结论MAPs具有免疫原性。经一种MAP免疫的小鼠可以产生对多种MAPs发生免疫反应的多克降抗体。并造成脏器损伤。 Objective To investigate the reactions after mice were immunized with multiple antigenic peptides (MAPs) of 60 000 SSA antigen. Methods Mice were immunized with different MAPs of 60 000 SSA and ELISA were used to detect anti-MAPs-antibodies in these mice. Lmmunohistochemical stain and HE stain were done to detect the anti-SSA autoantibodies and pathological damage in their hearts, livers and kidney. Results All groups of mice produced multiple-clone anti-MAPs antibodies, especially the mice of 482-495 group produced anti-MAP^9、10、20 antibodies as well as antibodies against other groups of MAPs. But the antibodies produced by the other groups of mice had no evident regularity. The immunohistochemical stain was negative in normal and adjuvant mice groups. In the 166-180, 401-411 and 482-495 groups of mice the immunohistochemical stain was negative in heart tissue was 80% positive in liver tissue and was suspiciously positive in kidney tissue. The HE stain was negative in all groups of mice. Conclusion MAPs have immunogenicity. Mice immunized with one group of MAPs can produced multi-clone antibodies and cause organ damage.
出处 《中华风湿病学杂志》 CAS CSCD 2007年第2期70-73,共4页 Chinese Journal of Rheumatology
基金 国家自然科学基金资助项目(30471618)
关键词 表位 SSA抗原 抗体 小鼠 Epitope SSA-antigen-antibody Mice
  • 相关文献

参考文献15

  • 1Deutscher SL, Harley JB. Molecular analysis of the 60 000 human Ro ribonucleoprotein. Proc Natl Acad Sci USA, 1988,85:9479-9483.
  • 2Tincani A, Biasini-Rebaioli C, Cattaneo R, et al. Nonorgan specific autoantibodies and heart damage. Lupus, 2005, 14: 656-659.
  • 3Synkowski DR, Reichlin M, Provost TT. Serum autoantibodies in systemic lupus erythematosus and correlation with cutaneous features. J Rheumatol, 1982, 9: 380-389.
  • 4Franceschini E, Cavazzana I. Anti-Ro/SSA and La/SSB antibodies. Autoimmunity, 2005, 38: 55-63.
  • 5Huang SC, Harley JB. Human anti-Ro antibodies bind peptides accessible to the surface of the native Ro autoantigen. J Scand Immunol, 1995, 41: 220-228.
  • 6Bahon-Riedinger I. Auto-antibodies to anti-ENA SSA/Ro(52 000and 60 000): an auto-immunity laboratory's experience. Rev Med Interne, 2004, 25: 421-428.
  • 7Saitta MR, Arnett FC, Keene JD, et al. 60 1300 Ro protein autoepitopes identifies using recombinant polypeptides. J Immunol,1994,152: 4192-4202.
  • 8Dickey WD, van Egmond JE, Hardgrave KL, et al. Presence of anti-La (SSB) is associated with binding to the 13 000 carboxyl terminus of 60 000 Ro (SSA)in systemic lupus erythematosus. J Invest Dermatol, 1993, 100: 412-416.
  • 9张奉春,JohnB.Harley,R.HalScofield,董怡.60 kD人SSA抗原表位免疫反应的特异性[J].中华风湿病学杂志,1998,2(1):5-9. 被引量:6
  • 10Scofield RH, Kurien BT, Gross JK, et al. Interaction of calcium and Ro60:increase of antigenicity. Mol Immunol, 2004, 41: 809-816.

共引文献13

同被引文献13

  • 1Boumia VK, Vlachoyiannopoulos PG. Subgroups of Sjtogren's syndrome patients according to serological profiles. J Autoimmun, 2012, 39: 15-26.
  • 2Scofield RH, Harley JB. Autoantigenicity of Ro/SSA antigen is related to a nueleocapsid protein of vesicular stomatitis virus. Proc Natl Acad Sci USA, 1991, 88: 3343-3347.
  • 3Huang SC, Yu H, Scofield RH, et al. Human anti-Ro antibodies bind peptides accessible to the surface of the native Ro autoanti- gen. J Seand I mmunot, 1995, 41 : 220-228.
  • 4Seofield RH, Asfa S, Obeso D, et al. Immunization with short peptides from the 60-kDa Ro antigen recapitulates the serological and pathological findings as well as the salivary gland dysfunction of Sjtigren's syndrome. J Immunol, 2005, 175: 8409-8414.
  • 5Keith D. AASLD practice guidelines: primary biliary cirrhosis. Hepatology, 2009, 50: 291-308.
  • 6Vitali C, Bombardieri S, Jonsson R, et al. European study group on classification criteria for Sjiigren's syndrome: a revised version of the European criteria proposed by the American-European consensus group. Ann Rheum Dis, 2002, 61 : 554-558.
  • 7Floreani A, arlola A, Niro G, et al. Plasma adipenectin levels in primary biliary cirrhosis: a novel perspective for link between hypercholesterolemia and protection against atherosclerosis. Am J Gastroenterol, 2008, 103: 1959-1965.
  • 8Alempijevic T, Sokic-Milutinovic A, Pavlovic-Markovic A, et al. Assessment of metabolic syndrome in patients with parimary bil- iary cirrhosis. Wien Klin Wochenschr, 2012, 124: 251-255.
  • 9Granito A, Muratori P, Muratori L,et al. Antibodies to SS-A/ Ro52kD and centromere in autoimmune liver disease: a clue to diagnosis and prognosis of primary biliary cirrhosis. Aliment Pharmacol Ther, 2007, 26: 831-838.
  • 10Staikou EV, Routsias JG, Makri AA, et al. Calretieulin binds preferentially with B cell linear epitopes of Ro60 kD autoantigen, enhancing recognition by anti-Ro60 kD autoantibodies. Clin Exp Irmnunol, 2003, 134: 143-150.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部